Clinical bottom line
Digital phenotyping—the continuous, real-time collection of behavioral and physiological data via smartphones and wearable devices—offers a promising but still preliminary approach to predicting suicide risk in patients with bipolar disorder. Emerging evidence suggests that digital markers such as changes in sleep patterns, activity levels, social communication, and mood variability may correlate with suicidal ideation or behavior. However, current data remain hypothesis-generating, with limited validation in large, diverse clinical populations. Clinicians should view digital phenotyping as a potential adjunct to, not a replacement for, comprehensive suicide risk assessment grounded in clinical evaluation and established risk factors (Rihmer et al., 2017; Gonzalez Mondejar et al., 2024).
What the evidence shows
Suicide risk in bipolar disorder is notably high, with estimates indicating that up to 20% of affected individuals may die by suicide (Katz et al., 2018; Choi et al., 2026). Traditional risk assessment relies on clinical history, symptom severity, and psychosocial factors, but these methods often lack predictive precision (Pompili et al., 2013). Digital phenotyping aims to fill this gap by passively capturing objective data streams reflecting mood, cognition, and behavior in real time.
Gonzalez Mondejar et al. (2024) demonstrated that digital phenotyping can identify behavioral signatures associated with mood episodes in bipolar disorder, which may precede suicidal crises. For example, decreased mobility, disrupted sleep, and reduced social interaction detected via smartphone sensors correlated with increased suicide risk markers. Enrique et al. (2024) further highlighted that integrating digital data with clinical assessments could enhance early detection of suicide risk, enabling timely intervention.
Substance use, a known moderator of suicide risk in adolescent bipolar disorder, may also be monitored through digital phenotyping by detecting patterns of risky behavior or irregular activity (Piersaint Tamare et al., 2014). This multidimensional data collection offers a dynamic risk profile rather than static snapshots.
Despite these promising findings, most studies remain small-scale or pilot investigations lacking replication. The heterogeneity of bipolar disorder presentations and variability in digital data quality pose challenges for generalizability (Rihmer et al., 2017). Moreover, ethical considerations around privacy and data security require careful management.
Caveats and uncertainty
The current evidence base for digital phenotyping in suicide risk prediction is largely exploratory and observational. There is no consensus on which digital biomarkers are most predictive or how to integrate them into clinical workflows. Many studies use proprietary algorithms or platforms, limiting reproducibility and external validation (Gonzalez Mondejar et al., 2024).
Confounding factors such as medication changes, comorbid conditions, and environmental stressors may influence digital signals, complicating interpretation. Additionally, digital phenotyping may be less feasible or acceptable for certain patient populations, including older adults or those with limited technology access.
Importantly, no digital phenotyping tool has yet undergone rigorous prospective validation as a standalone suicide risk predictor in bipolar disorder. Thus, these approaches should not be used in isolation to make clinical decisions about suicide risk or management (Choi et al., 2026).
How this may change practice
Digital phenotyping holds potential to augment suicide risk assessment by providing continuous, objective data that complement traditional clinical evaluation. In the future, clinicians may integrate digital markers into measurement-based care models to identify early warning signs of suicidal ideation or behavior, enabling proactive interventions.
For now, clinicians should remain informed about emerging digital tools but apply them cautiously, ensuring they supplement rather than supplant comprehensive risk assessment. Collaborative care models incorporating mental health professionals, data scientists, and ethicists will be essential to develop validated, user-friendly digital phenotyping platforms.
Clinicians may consider discussing digital monitoring options with patients who are comfortable with technology and motivated for self-management, emphasizing privacy safeguards and the adjunctive nature of these tools. Ongoing research and clinical trials will clarify the utility and implementation pathways for digital phenotyping in bipolar disorder suicide prevention.